Pharmaceuticals
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
7938
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
4817
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...
2026-01-13 07:30
4657
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"),
a clinical-stage, generative AI-driven drug discovery company, today announced
the completion of first patient first dose in BETHESDA: a Phase IIa clinical
trial of ISM5411 (NCT07265570
2026-01-12 21:30
3170
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveragin...
2026-01-12 21:05
6450
Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an ex...
2026-01-12 20:00
4716
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol...
2026-01-12 16:00
4537
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's
Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2026-01-12 12:33
434
Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This c...
2026-01-09 20:00
5626
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2026-01-09 08:00
5704
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antib...
2026-01-09 08:00
4196
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
3773
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC...
2026-01-08 00:00
6644
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update inChina for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final a...
2026-01-07 10:50
8343
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...
2026-01-07 10:44
9447
VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...
2026-01-07 00:00
392
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...
2026-01-06 22:30
1239
Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* - SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ ...
2026-01-06 21:29
4375
Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO:Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to supp...
2026-01-06 21:00
381
Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain
* Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. * QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hou...
2026-01-05 23:00
7385
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 307 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 289 media titles]
2026-05-18 15:30
AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
7995
